20 research outputs found
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis
BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
BACKGROUND
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few
effective long-term treatments are available. In cardiovascular trials of inhibitors
of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested
that such drugs may improve renal outcomes in patients with type 2 diabetes.
METHODS
In this double-blind, randomized trial, we assigned patients with type 2 diabetes
and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2
inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated
glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2
of bodysurface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to
5000) and were treated with renin–angiotensin system blockade. The primary
outcome was a composite of end-stage kidney disease (dialysis, transplantation, or
a sustained estimated GFR of <15 ml per minute per 1.73 m2
), a doubling of the
serum creatinine level, or death from renal or cardiovascular causes. Prespecified
secondary outcomes were tested hierarchically.
RESULTS
The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had
undergone randomization, with a median follow-up of 2.62 years. The relative risk
of the primary outcome was 30% lower in the canagliflozin group than in the
placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001).
The relative risk of the renal-specific composite of end-stage kidney disease, a
doubling of the creatinine level, or death from renal causes was lower by 34%
(hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of endstage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86;
P=0.002). The canagliflozin group also had a lower risk of cardiovascular death,
myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)
and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80;
P<0.001). There were no significant differences in rates of amputation or fracture.
CONCLUSIONS
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and
cardiovascular events was lower in the canagliflozin group than in the placebo group
at a median follow-up of 2.62 years. (Funded by Janssen Research and Development;
CREDENCE ClinicalTrials.gov number, NCT02065791.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
From compliance to co-production: emergent forms of agency in sustainable wine production in New Zealand
This article engages with non-human agency through the interrogation of the emerging role of metrics in the governance of sustainability in the New Zealand primary sector. In it, we argue that the agency of the metrics builds on previous work that has elaborated the impact of audited best practice on the subjectivities of producers and processors, including the recent examination of the active influence of metrics that engenders unexpected and uncontrolled change in social networks of production. In this case, the analysis of the influence of metrics shifts to those used within a recently introduced ‘learning’ tool (Wine Industry Sustainability Engine) that can be classified as an effort in transition management. The capacity of metrics as agents is already apparent in the perceived interactions and engagements with the Wine Industry Sustainability Engine tool as expressed by likely users during assessments of the usability of initial pilot software. Using their response, we demonstrate that, despite intentions to use the tool to foster particular sets of practices and ethics through benchmarking, the metrics have multiple roles in production worlds—compelling compliance to regulations, creating new ways to communicate complex relations and practices, and generating information for reflexive self-evaluation. Through these roles, we argue, metrics clearly operate as both a material and ontological non-human actor, expressed in different ways in different assemblages. This conclusion has implications for the application of transition management more broadly, and helps us to better understand what we want metrics to accomplish, what they can accomplish, and the possible gap between the two
Performance versus values in sustainability transformation of food systems
Questions have been raised on what role the knowledge provided by sustainability science actually plays in the transition to sustainability and what role it may play in the future. In this paper we investigate different approaches to sustainability transformation of food systems by analyzing the rationale behind transformative acts-the ground that the direct agents of change act upon- and how the type of rationale is connected to the role of research and how the agents of change are involved. To do this we employ Max Weber’s distinction between instrumental rationality and value-rationality in social action. In particular, we compare two different approaches to the role of research in sustainability transformation: (1) Performance-based approaches that measure performance and set up sustainability indicator targets and benchmarks to motivate the agents in the food system to change; (2) Values-based approaches that aim at communicating and mediating sustainability values to enable coordinated and cooperative action to transform the food system. We identify their respective strengths and weaknesses based on a cross-case analysis of four cases, and propose that the two approaches, like Weber’s two types of rationality, are complementary-because they are based on complementary observer stances—and that an optimal in-between approach therefore cannot be found. However, there are options for reflexive learning by observing one perspective-and its possible blind spots-from the vantage point of the other, so we suggest that new strategies for sustainability transformation can be found based on reflexive rationality as a third and distinct type of rationalit
Distribution, feeding and growth of hatchery-reared Atlantic salmon (Salmo salar L.) parr stocked into rivers with various abiotic conditions
Within the research of efficiency of Atlantic salmon the artificial reproduction, feeding rate, distribution and growth of farm-raised one-year-old Atlantic salmon have been examined. The fish has been released into nursery areas with different hydrological characteristics located in the Rivers Kola, Umba, Srednyaya and Akkim in the Murmansk region. The observations have being conducted for 1–5 months since the moment of fish release. In natural habitat, juveniles rapidly distribute downstream and upstream regardless of water temperature, depth and current velocity. In all examined nursery areas adapting one-year-old juveniles prefer to stay at weak current sites close to the shore, hiding in the gravel. In all the cases farmed parr shows high feed rate, but qualitative composition of their food differs significantly from food composition of wild juveniles. Revealed peculiarities of adapting parr's distribution and qualitative food composition indicate the impact of long-term rearing at hatcheries on fish behavior. Growth rate of one-year-old juveniles is arcwise connected with fraction composition of gravel and the level of bottom fouling: the bigger bottom rocks are and the thicker the fouling is, the more intensive fish growth is. The revealed correlations have been described with equations of linear regression. Connections between juvenile growth and water temperature, current velocity and depth of the area have not been detected. The research outcomes could provide a basis for scientific advice for planning release sites and number of released one-year-old Atlantic salmon by hatcheries in the Murmansk region